Welcome to our dedicated page for Beigene news (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on Beigene stock.
News about BeiGene, Ltd. (BGNE) centers on its role as a global oncology company advancing cancer medicines such as TEVIMBRA (tislelizumab) and BRUKINSA (zanubrutinib), along with a broad pipeline of solid tumor and hematology assets. The company’s announcements frequently cover regulatory milestones, clinical trial readouts, licensing deals and strategic updates tied to its oncology focus.
Recent news highlights include positive regulatory developments for TEVIMBRA, such as a positive opinion from the Committee for Medicinal Products for Human Use for first-line treatment of extensive-stage small cell lung cancer in combination with chemotherapy, European Commission approvals in first-line esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma, and U.S. Food and Drug Administration approval for first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. These stories typically detail Phase 3 trial results, overall survival outcomes and safety profiles.
BeiGene’s news flow also features updates from major scientific meetings, including new data from the SEQUOIA study of BRUKINSA in chronic lymphocytic leukemia/small lymphocytic lymphoma, early-phase results for sonrotoclax and BGB‑16673 in B‑cell malignancies, and broader pipeline presentations at forums such as the American Society of Hematology Annual Meeting. Additional items include a global licensing agreement for the MAT2A inhibitor SYH2039 for MTAP-deleted solid tumors and partnerships like the Test Before Treat campaign with CLL Society to promote biomarker testing in CLL/SLL.
Investors and followers of BGNE can use this news page to track regulatory decisions, clinical data releases, business development agreements, investor conference appearances and corporate identity plans, including BeiGene’s stated intent to change its name to BeOne Medicines Ltd. and its Nasdaq ticker symbol to ONC.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BeiGene has announced its plan to present significant data at the upcoming ASCO Annual Meeting from June 2-6, 2023, in Chicago. The data highlights two promising drug candidates: the anti-OX40 agnostic antibody BGB-A445 and the BCL-2 inhibitor BGB-11417, alongside its cornerstone assets zanubrutinib and tislelizumab. Lead presentations will include results from pivotal studies in treating various cancers, showcasing the company’s commitment to improving treatment outcomes.
This strategic focus on oncology underlines BeiGene's robust R&D efforts led by Lai Wang, Ph.D. The company is poised to advance its pipeline of innovative therapies aimed at enhancing patient access to effective treatments.
BeiGene (NASDAQ: BGNE) announced the successful outcomes of the global RATIONALE 305 trial, indicating that tislelizumab in combination with chemotherapy significantly improved overall survival (OS) in patients with advanced gastric or gastroesophageal junction adenocarcinoma. The trial met its primary endpoint, demonstrating superior OS over chemotherapy alone, regardless of PD-L1 status. No new safety concerns were noted, reinforcing the drug's safety profile.
The findings will be presented at an upcoming medical conference, supporting the potential of tislelizumab as a first-line treatment option. This development aligns with BeiGene's ongoing regulatory efforts for tislelizumab in various cancers, marking a significant milestone as gastric cancer remains a prevalent and challenging condition globally.